Gsk (GLAXF) EPS (Weighted Average and Diluted) (2009 - 2022)
Gsk (GLAXF) recorded quarterly EPS (Weighted Average and Diluted) of -$16580.9 in Q4 2022, down 235.89% quarter-over-quarter from $12201.5 in Q3 2022, and down 1422.61% on a YoY basis from $1253.6 in Q4 2021.
Gsk (GLAXF) EPS (Weighted Average and Diluted) (2009 - 2022) Analysis & Trends
Gsk's EPS (Weighted Average and Diluted) history runs 7 years deep, the most recent figure standing at -$16580.9 for Q4 2022.
- In Q4 2022, EPS (Weighted Average and Diluted) fell 1422.61% year-over-year to -$16580.9; the TTM figure through Dec 2022 stood at -$217.99 (down 103.1% YoY), while the FY2025 annual figure was $1.83, up 130.18% from the prior year.
- EPS (Weighted Average and Diluted) was -$16580.9 for Q4 2022 at Gsk, down from $12201.5 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $12201.5 in Q3 2022 to a low of -$16580.9 in Q4 2022.
- Historically, EPS (Weighted Average and Diluted) has averaged $694.39 across 3 years, with a median of $1811.7 in 2021.
- The sharpest annual moves came in 2018 and 2022: EPS (Weighted Average and Diluted) soared 100615.73% in 2018, then slumped 1422.61% in 2022.
- A 3-year view of EPS (Weighted Average and Diluted) shows it stood at $0.05 in 2018, then jumped by 2534601.91% to $1253.6 in 2021, then slumped by 1422.61% to -$16580.9 in 2022.
- The last three EPS (Weighted Average and Diluted) figures came in at -$16580.9 (Q4 2022), $12201.5 (Q3 2022), and $2907.8 (Q1 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 8.26 |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 2.14 |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 0.39 |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -1.72 |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 3.34 |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 1.61 |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 0.47 |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 1.31 |
| 10 | Gsk | - | - | 7.76 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -16,580.91 |
| Sep 30, 2022 | 12,201.51 |
| Mar 31, 2022 | 2,907.76 |
| Dec 31, 2021 | 1,253.65 |
| Sep 30, 2021 | 1,885.90 |
| Jun 30, 2021 | 2,149.71 |
| Mar 31, 2021 | 1,737.44 |
| Mar 31, 2018 | 0.05 |
| Mar 31, 2017 | 0.00 |
| Sep 30, 2011 | 0.00 |
| Jun 30, 2011 | 0.04 |
| Mar 31, 2011 | 0.05 |
| Dec 31, 2010 | -0.02 |
| Sep 30, 2010 | 0.00 |
| Jun 30, 2010 | -0.11 |
| Mar 31, 2010 | 0.05 |
| Dec 31, 2009 | 0.00 |
| Sep 30, 2009 | 0.05 |
| Mar 31, 2009 | 0.05 |